Pipelines & Platforms
Biologics   1.PD-L1 mAb   2.CSF-1R mAb   3.Globo H/IO CAR-T (DCBGM2302) / Gastric Cancer   4.NTSR1 ADC (DCBAD2301) / Head and Neck Cancer   5.B7-H3 ADC (DCBAD2303) / B7-H3-positive Tumors
Pharmaceutics   1.Raf Inhibitor / Melanoma   2.FPR1 Inhibitor / Neutrophil Related Inflammatory Diseases   3.TXNDC5 Oligonucleotide Drug / Idiopathic Pulmonary Fibrosis
Platforms   1.Human Synthetic Antibody Library for Therapeutic Drug Discovery   2.The High Yield Therapeutic mRNA Production Platform   3.Oligonucleotide Delivery Platform: Novel Sequential GalNAc Linker
Business Interests
In-Licensing, Out-Licensing, Collaborative R&D, CDMO, CRO, Co-Development, Strategic Alliance
Contact Info
Ching-Hsu Yang
Research Fellow
+886-2-7700-3800 #5293
ch.yang@dcb.org.tw